Biotechnology

AACR 2023 | ImmVira presented preclinical study results of first CAR-T enabler oncolytic product MVR-T7011 at AACR Annual Meeting

SHENZHEN, China, April 17, 2023 /PRNewswire/ -- On April 18, 2023, U.S. time, ImmVira presented preclinical study results of CAR-T enabler oHSV product MVR-7011 through poster publication at the American Association for Cancer Research ("AACR") annual meeting.

2023-04-19 08:29 1733

Bridge Biotherapeutics Releases Updated Preclinical Data for BBT-207 at the AACR Annual Meeting

* New preclinical data validate anti-tumor efficacy and intracranial activity of the drug candidate * Bridge submitted an IND application to the U.S. Food and Drug Administration in March, and expects to initiate the first-in-human study of BBT-207 this year SEONGNAM, South Korea and CAMBRIDG...

2023-04-19 07:00 1792

South Korean Biotech, ToolGen Leads the Development of Numerous Cutting-Edge Genome Editing Techniques

SEOUL, South Korea, April 18, 2023 /PRNewswire/ -- Until now, most of the major breakthroughs in the CRISPR field have been led by US academics. Not anymore; Toolgen, aSouth Korea-based biotech company, has reported three breakthrough techniques in top-tier scientific journals.

2023-04-18 21:00 1665

Technoderma Medicines Initiates TDM-105795 Androgenetic Alopecia Phase 2 Clinical Trial

CHENGDU, China, April 18, 2023 /PRNewswire/ -- Technoderma Medicines, Inc. ("the Company"), a clinical stage biopharmaceutical company, is pleased to report that the Company has begun dosing patients in its Androgenetic Alopecia (AGA) Phase 2 clinical trial (NCT05802173) of topical TDM-105795 sol...

2023-04-18 21:00 1495

GC Biopharma celebrates 'World Hemophilia Day'

* To display a large media façade on its Yong-in R&D Center YONGIN, South Korea, April 17, 2023 /PRNewswire/ -- GC Biopharma (006280.KS), a leading provider of biopharmaceutical products inSouth Korea, takes part in a campaign to celebrate World Hemophilia Day. The company announced that a l...

2023-04-18 09:03 1654

Innovent Releases Final Analysis Results of ORIENT-16: the Phase 3 Study of Sintilimab in Combination with Chemotherapy for the First-Line Treatment of Gastric Cancer at the AACR Annual Meeting 2023

ROCKVILLE, Md. and SUZHOU, China, April 17, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology a...

2023-04-18 08:00 2200

Promising Efficacy of AT101 CAR-T for Blood Cancer

SEOUL, South Korea, April 17, 2023 /PRNewswire/ -- AbClon, a South Korean biotech firm, presented non-clinical and phase 1 interim results of its AT101 novel CAR-T therapy at the annual 2023 AACR conference. AT101 targets the CD19 protein for treatment of blood cancer. AT101 demonstrated superio...

2023-04-18 02:00 1679

Innovent Releases Final Analysis Results of ORIENT-15: the Phase 3 Study of Sintilimab plus Chemotherapy for the First-Line Treatment of Esophageal Squamous Cell Carcinoma at the AACR Annual Meeting 2023

ROCKVILLE, Md. and SUZHOU, China, April 16, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology a...

2023-04-17 08:20 3116

Introducing the MetaSight® G200: A Revolutionary Third-Generation Chromosomal Karyotyping System Transforming Global Chromosomal Analysis

CHANGSHA, China, April 15, 2023 /PRNewswire/ -- The MetaSight® G200 is a groundbreaking karyotyping system based on high-resolution microscopy technology, capable of accurately detecting chromosomal abnormalities in humans. This innovative system aids doctors in diagnosing and treating diseases ...

2023-04-15 14:43 3122

Minghui Pharmaceutical Inc. Announces Phase 2 Clinical Trial Success of MH004 Cream as a Potential Best-in-Class Topical Treatment for Mild-to-Moderate Atopic Dermatitis and the FDA Clearance of its Global Phase 3 MRCT

* Study met both primary and all key secondary endpoints * Mean percentage change from baseline in Eczema Area and Severity Index (EASI) score was -78.7% in 1.0% MH004 Cream-treated group compared to -46.7% in vehicle group * 79.6% individuals treated with 1.0% MH004 Cream achieved EASI-75 c...

2023-04-14 19:00 6499

Zenshine Pharmaceuticals' ZX-7101A Met the Primary Endpoint of the Phase 2 Study for the Treatment of Acute Uncomplicated Influenza in Adults

NANJING, China, April 13, 2023 /PRNewswire/ -- On April 1st, 2023, during the First Infection Collaboration Forum of the Chinese National Center for Infectious Diseases, Nanjing Zenshine Pharmaceuticals Co., Ltd. (Zenshine Pharmaceuticals) announced that its proprietary anti-influenza agent ZX-71...

2023-04-14 01:15 1989

Viva Biotech Attended SAPA-China

HONG KONG, April 12, 2023 /PRNewswire/ -- 6th-7th April, the "2022 SAPA-China Annual Conference - Opportunities and Challenges for the Development ofChina's Biopharmaceutical Industry" hosted by The Sino-American Pharmaceutical Professionals Association (SAPA) was held inChengdu, Sichuan. Viva Bi...

2023-04-13 11:33 2268

Bridge Biotherapeutics Announces First Patient Dosed in its Phase 2a Clinical Trial of BBT-877, a Potent Autotaxin Inhibitor for the Treatment of Idiopathic Pulmonary Fibrosis

SEONGNAM, South Korea and CAMBRIDGE, Mass., April 12, 2023 /PRNewswire/ -- Bridge Biotherapeutics (KQ288330), a clinical-stage biotech company based in South Korea developing novel drugs for fibrosis, cancer, and inflammation, announced it has dosed the first patient in its Phase 2a clinical study...

2023-04-13 06:00 1865

Standigm announces Younsung Choo as chief executive officer

Former LG life Sciences exec and long-time Standigm advisor brings extensive experience in pharmaceuticals and project management SEOUL, South Korea, April 12, 2023 /PRNewswire/ -- Standigm , a company using artificial intelligence (AI) technology for drug discover...

2023-04-13 00:07 2065

CHITOSE Group Obtains Funding from Japanese Government-affiliated NEDO for Green Innovation Fund of USD400M Range

KAWASAKI, Japan and SINGAPORE, April 12, 2023 /PRNewswire/ -- Chitose Laboratory Corp., the core company of the CHITOSE Group (hereinafter "CHITOSE"), has won funding from a Japanese government-affiliated entity for a project on the self-proposed theme of "Building a global industry originating ...

2023-04-12 14:17 1907

GC Genome-KAIST team Announces Publication of a Groundbreaking AI-Based Liquid Biopsy Technology for Multi-Cancer Early Detection and Localization in Nature Communications

YONGIN, South Korea, April 11, 2023 /PRNewswire/ -- GC Genome Corporation, a leading genomic diagnostics company, today announced the publication of a new study inNature Communications, showcasing the company's novel AI-based liquid biopsy technology. The study highlights the unprecedented accura...

2023-04-12 11:06 1744

Lunit Demonstrates Progress in the Development of Novel Diagnostics at the 2023 AACR Annual Meeting

* Lunit and collaborators demonstrate key progress in the development of novel diagnostics for cancer therapies, including immuno-oncology, in addition to molecular targeted agents and antibody-drug conjugates * Presentations to deliver new research using Lunit SCOPE in a wide range of cancer...

2023-04-11 21:00 2005

Origin Agritech GMO Corn Hybrid is the One and Only Triple Stack Trait Corn Selected for National Demo Plot, Being Grown There in Anticipation of 2023 Commercial Launch

BEIJING, April 11, 2023 /PRNewswire/ -- Origin Agritech Ltd. (NASDAQ: SEED) (the "Company" or "Origin"), announced today that its GMO corn hybrid is the one and only triple stacked trait corn selected for the national demo plot and is currently being grown there in anticipation of a 2023 commerci...

2023-04-11 20:45 1875

OnCusp Therapeutics Showcases Potent Anti-Tumor Activity of its CDH6 ADC at AACR Annual Meeting 2023

NEW YORK, April 11, 2023 /PRNewswire/ -- OnCusp Therapeutics, a global biopharmaceutical company dedicated to transforming cutting-edge preclinical innovation into clinically validated treatments for cancer patients worldwide, today announced that the preclinical data on its lead program CUSP0...

2023-04-11 20:00 1464

Asieris' subsidiary makes significant progress in its commercialization strategy by obtaining the "Drug Distribution License"

SHANGHAI, April 10, 2023 /PRNewswire/ -- Asieris Pharmaceuticals (688176), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced that its subsidiary, Hainan Yahong ph...

2023-04-10 20:18 2143
1 ... 54555657585960 ... 129

Week's Top Stories